KalVista Pharmaceuticals (FRA:4XC1) FCF Margin % : 0.00% (As of Jul. 2024)

View and export this data going back to 2016. Start your Free Trial

What is KalVista Pharmaceuticals FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. KalVista Pharmaceuticals's Free Cash Flow for the three months ended in Jul. 2024 was €-37.16 Mil. KalVista Pharmaceuticals's Revenue for the three months ended in Jul. 2024 was €0.00 Mil. Therefore, KalVista Pharmaceuticals's FCF Margin % for the quarter that ended in Jul. 2024 was 0.00%.

As of today, KalVista Pharmaceuticals's current FCF Yield % is -22.77%.

The historical rank and industry rank for KalVista Pharmaceuticals's FCF Margin % or its related term are showing as below:

During the past 13 years, the highest FCF Margin % of KalVista Pharmaceuticals was 108.78%. The lowest was -1582.18%. And the median was -357.41%.

FRA:4XC1's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -143.325
* Ranked among companies with meaningful FCF Margin % only.

KalVista Pharmaceuticals FCF Margin % Historical Data

The historical data trend for KalVista Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

KalVista Pharmaceuticals FCF Margin % Chart

KalVista Pharmaceuticals Annual Data

Trend

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Apr24

FCF Margin %

Get a 7-Day Free Trial

-354.89

KalVista Pharmaceuticals Quarterly Data
	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of KalVista Pharmaceuticals's FCF Margin %

For the Biotechnology subindustry, KalVista Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

KalVista Pharmaceuticals's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, KalVista Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where KalVista Pharmaceuticals's FCF Margin % falls into.

KalVista Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

KalVista Pharmaceuticals's FCF Margin for the fiscal year that ended in Apr. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Apr. 2024 )	/	Revenue (A: Apr. 2024 )
	=	-83.576	/	0
	=	%

KalVista Pharmaceuticals's FCF Margin for the quarter that ended in Jul. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jul. 2024 )	/	Revenue (Q: Jul. 2024 )
	=	-37.161	/	0
	=	%

KalVista Pharmaceuticals FCF Margin % Related Terms

Thank you for viewing the detailed overview of KalVista Pharmaceuticals's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

KalVista Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » KalVista Pharmaceuticals Inc (FRA:4XC1) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

KALV:USA

Address

55 Cambridge Parkway, Suite 901 East, Cambridge, MA, USA, 02142

Website

https://www.kalvista.com

KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States.

KalVista Pharmaceuticals Headlines

No Headlines